Allogene Therapeutics Stock Forecast - Naive Prediction
| ALLO Stock | USD 1.72 0.12 7.50% |
The Naive Prediction forecasted value of Allogene Therapeutics on the next trading day is expected to be 1.73 with a mean absolute deviation of 0.05 and the sum of the absolute errors of 2.94. Allogene Stock Forecast is based on your current time horizon. Although Allogene Therapeutics' naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Allogene Therapeutics' systematic risk associated with finding meaningful patterns of Allogene Therapeutics fundamentals over time.
As of today the rsi of Allogene Therapeutics' share price is below 20 . This suggests that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter (0.22) | EPS Estimate Current Year (0.92) | EPS Estimate Next Year (0.89) | Wall Street Target Price 7.3833 | EPS Estimate Current Quarter (0.23) |
Using Allogene Therapeutics hype-based prediction, you can estimate the value of Allogene Therapeutics from the perspective of Allogene Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Allogene Therapeutics using Allogene Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Allogene using crowd psychology based on the activity and movement of Allogene Therapeutics' stock price.
Allogene Therapeutics Short Interest
An investor who is long Allogene Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about Allogene Therapeutics and may potentially protect profits, hedge Allogene Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 1.2985 | Short Percent 0.0969 | Short Ratio 6.88 | Shares Short Prior Month 18 M | 50 Day MA 1.4374 |
Allogene Therapeutics Hype to Price Pattern
Investor biases related to Allogene Therapeutics' public news can be used to forecast risks associated with an investment in Allogene. The trend in average sentiment can be used to explain how an investor holding Allogene can time the market purely based on public headlines and social activities around Allogene Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Allogene Therapeutics Implied Volatility | 1.8 |
Allogene Therapeutics' implied volatility exposes the market's sentiment of Allogene Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Allogene Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Allogene Therapeutics stock will not fluctuate a lot when Allogene Therapeutics' options are near their expiration.
The Naive Prediction forecasted value of Allogene Therapeutics on the next trading day is expected to be 1.73 with a mean absolute deviation of 0.05 and the sum of the absolute errors of 2.94. Allogene Therapeutics after-hype prediction price | USD 1.72 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Allogene Therapeutics to cross-verify your projections. Prediction based on Rule 16 of the current Allogene contract
Based on the Rule 16, the options market is currently suggesting that Allogene Therapeutics will have an average daily up or down price movement of about 0.11% per day over the life of the 2026-03-20 option contract. With Allogene Therapeutics trading at USD 1.72, that is roughly USD 0.001935 . If you think that the market is fully incorporating Allogene Therapeutics' daily price movement you should consider acquiring Allogene Therapeutics options at the current volatility level of 1.8%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-03-20 Allogene Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Allogene Therapeutics' spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Allogene Therapeutics' options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Allogene Therapeutics stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Allogene Therapeutics' open interest, investors have to compare it to Allogene Therapeutics' spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Allogene Therapeutics is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Allogene. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Allogene Therapeutics Additional Predictive Modules
Most predictive techniques to examine Allogene price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Allogene using various technical indicators. When you analyze Allogene charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Allogene Therapeutics Cash Forecast
Forecasting financial indicators like cash flow involves analysts applying various statistical methods, techniques, and algorithms. These tools reveal hidden trends within the Allogene Therapeutics' financial statements to estimate their effects on upcoming price movements.
Cash | First Reported 2018-03-31 | Previous Quarter 52.3 M | Current Value 37.8 M | Quarterly Volatility 155.4 M |
Allogene Therapeutics Naive Prediction Price Forecast For the 26th of January
Given 90 days horizon, the Naive Prediction forecasted value of Allogene Therapeutics on the next trading day is expected to be 1.73 with a mean absolute deviation of 0.05, mean absolute percentage error of 0, and the sum of the absolute errors of 2.94.Please note that although there have been many attempts to predict Allogene Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Allogene Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Allogene Therapeutics Stock Forecast Pattern
| Backtest Allogene Therapeutics | Allogene Therapeutics Price Prediction | Buy or Sell Advice |
Allogene Therapeutics Forecasted Value
In the context of forecasting Allogene Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Allogene Therapeutics' downside and upside margins for the forecasting period are 0.02 and 6.48, respectively. We have considered Allogene Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Allogene Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Allogene Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 112.5724 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0482 |
| MAPE | Mean absolute percentage error | 0.0344 |
| SAE | Sum of the absolute errors | 2.9402 |
Predictive Modules for Allogene Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Allogene Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Allogene Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Allogene Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Allogene Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Allogene Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Allogene Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Allogene Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Allogene Therapeutics' historical news coverage. Allogene Therapeutics' after-hype downside and upside margins for the prediction period are 0.09 and 6.47, respectively. We have considered Allogene Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Allogene Therapeutics is very risky at this time. Analysis and calculation of next after-hype price of Allogene Therapeutics is based on 3 months time horizon.
Allogene Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Allogene Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Allogene Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Allogene Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.65 | 4.75 | 0.00 | 0.60 | 8 Events / Month | 7 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.72 | 1.72 | 0.00 |
|
Allogene Therapeutics Hype Timeline
Allogene Therapeutics is presently traded for 1.72. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.6. Allogene is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is expected to be very small, whereas the daily expected return is presently at 0.65%. %. The volatility of related hype on Allogene Therapeutics is about 512.41%, with the expected price after the next announcement by competition of 2.32. About 17.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.23. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allogene Therapeutics recorded a loss per share of 0.98. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 8 days. Check out Historical Fundamental Analysis of Allogene Therapeutics to cross-verify your projections.Allogene Therapeutics Related Hype Analysis
Having access to credible news sources related to Allogene Therapeutics' direct competition is more important than ever and may enhance your ability to predict Allogene Therapeutics' future price movements. Getting to know how Allogene Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Allogene Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| EDIT | Editas Medicine | 0.23 | 9 per month | 0.00 | (0.21) | 6.56 | (9.13) | 18.33 | |
| CABA | Cabaletta Bio | 2.00 | 7 per month | 4.89 | 0.05 | 10.58 | (8.79) | 62.77 | |
| CRBU | Caribou Biosciences | 2.56 | 3 per month | 0.00 | (0.22) | 6.86 | (8.76) | 20.16 | |
| AVIR | Atea Pharmaceuticals | 1.60 | 6 per month | 2.89 | 0.11 | 4.64 | (3.27) | 16.12 | |
| HUMA | Humacyte | 1.60 | 16 per month | 0.00 | (0.16) | 8.16 | (8.13) | 19.22 | |
| VNDA | Vanda Pharmaceuticals | 1.60 | 13 per month | 4.85 | 0.12 | 11.39 | (6.34) | 39.51 | |
| VYGR | Voyager Therapeutics | (0.17) | 9 per month | 0.00 | (0.11) | 4.58 | (5.23) | 19.71 | |
| KYTX | Kyverna Therapeutics Common | (0.47) | 9 per month | 7.85 | 0.08 | 10.86 | (9.60) | 55.75 | |
| ACHV | Achieve Life Sciences | 0.05 | 20 per month | 3.42 | 0.04 | 5.86 | (5.83) | 21.45 | |
| IMMP | Immutep Ltd ADR | 0.27 | 6 per month | 2.90 | 0.14 | 7.41 | (5.41) | 31.54 |
Other Forecasting Options for Allogene Therapeutics
For every potential investor in Allogene, whether a beginner or expert, Allogene Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Allogene Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Allogene. Basic forecasting techniques help filter out the noise by identifying Allogene Therapeutics' price trends.Allogene Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Allogene Therapeutics stock to make a market-neutral strategy. Peer analysis of Allogene Therapeutics could also be used in its relative valuation, which is a method of valuing Allogene Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Allogene Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Allogene Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Allogene Therapeutics shares will generate the highest return on investment. By undertsting and applying Allogene Therapeutics stock market strength indicators, traders can identify Allogene Therapeutics entry and exit signals to maximize returns.
Allogene Therapeutics Risk Indicators
The analysis of Allogene Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Allogene Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting allogene stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.53 | |||
| Semi Deviation | 3.24 | |||
| Standard Deviation | 4.66 | |||
| Variance | 21.73 | |||
| Downside Variance | 15.38 | |||
| Semi Variance | 10.49 | |||
| Expected Short fall | (5.02) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Allogene Therapeutics
The number of cover stories for Allogene Therapeutics depends on current market conditions and Allogene Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Allogene Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Allogene Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Allogene Therapeutics Short Properties
Allogene Therapeutics' future price predictability will typically decrease when Allogene Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Allogene Therapeutics often depends not only on the future outlook of the potential Allogene Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Allogene Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 194.8 M | |
| Cash And Short Term Investments | 292.5 M |
Check out Historical Fundamental Analysis of Allogene Therapeutics to cross-verify your projections. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.